MODEL VERDICT
Seres Therapeutics, Inc. (MCRB) — Relative Valuation
Peer multiples, Monte Carlo simulation & quality-adjusted fair value
Popular:
Seres Therapeutics, Inc. (MCRB)
Seres Therapeutics, Inc. (MCRB) — Relative ValuationPeer multiples, Monte Carlo simulation & quality-adjusted fair value
Seres Therapeutics, Inc. (MCRB)
Composite score derived from valuation, quality, and risk factors
Quantitative model thresholds · For educational and research purposes only
Cross-sectional regression predicting expected multiples based on growth, margins, ROIC, and beta.
| Multiple | Avg | Median | Min | Max | Std |
|---|---|---|---|---|---|
| P/TBV | 20.62 | 10.28 | 5.81 | 56.13 | 23.78 |
| P/B Ratio | 20.62 | 10.28 | 5.81 | 56.13 | 23.78 |
| P/S Ratio | 19.08 | 6.09 | 5.27 | 58.85 | 26.52 |
Insufficient data to determine relative valuation for MCRB.
Fair value could not be computed for MCRB due to insufficient comparable data.
MCRB's current P/E of -0.8x compares to the industry median of 23.5x (45 peers in the group). This represents a -103.3% discount to the industry. The historical average P/E is N/Ax over 0 years. Signal: Deep Discount.
18 analysts cover MCRB with a consensus rating of Buy. The consensus price target is $1.25 (range: $1.25 — $1.25), implying -91.5% upside from the current price. Grade breakdown: Strong Buy (0), Buy (11), Hold (3), Sell (4), Strong Sell (0).
The model confidence score is 43/100, based on: data completeness (0), peer quality (25), historical depth (10), earnings stability (5), and model agreement (3). Cyclicality penalty: -0 points. The model shows moderate agreement across inputs.
The model flags several key risks: (1) Macro/regulatory risks are not captured in this model but remain material.
Peak earnings risk data is not available for MCRB.
No. This dashboard is a quantitative research tool for educational and informational purposes only. It is not investment advice, a solicitation, or a recommendation to buy, sell, or hold any security. The operator of this platform is not a registered investment advisor (RIA), broker-dealer, or financial planner. All model outputs, fair value estimates, signals, and scenarios are the result of automated quantitative computations and should not be construed as professional financial guidance. You should consult a qualified, licensed financial advisor before making any investment decisions. Past model performance is not indicative of future results.